This is the master watchlist of the 12 peptides most likely to materially change the prescribed-medication landscape between 2026 and 2028. The list is not a marketing ranking. It is the operational watchlist a prescriber tracks in 2026 to anticipate what will be available in 2027, 2028, and beyond.
Three framing notes before the list:
Approved peptides today. As of May 2026, the prescribed-peptide landscape relevant to TelePeptide is anchored by approved GLP-1-class agents (semaglutide, tirzepatide, liraglutide), approved GHRH analogs (sermorelin, tesamorelin), and a handful of approved peptides in narrower indications. The compounds on the watchlist below are additional — they would expand the prescribing landscape on top of what is currently available, not replace existing options entirely.
Approval is not a single event. Each compound on the watchlist is at a specific phase in clinical development with specific readouts and submission events between now and approval. "Coming soon" is not the same as "imminently available." The earliest plausible decisions on this list are in 2026 to 2027; the later ones are in 2028.
Compounded versions of investigational compounds are not the investigational compounds. This is the recurring honesty point. A vial labeled "retatrutide" or "MariTide" sourced from a research-grade peptide supplier is not the FDA-investigational compound; it is a research-grade peptide of unknown identity, purity, and potency. The fact that someone is willing to sell something with a name on it does not mean it is the medication.
The 12-peptide watchlist
The compounds are organized by mechanism class. Each entry includes sponsor, mechanism, current phase, expected earliest FDA decision, and a one-line differentiation statement.
GLP-1 mono-agonists
1. Orforglipron (oral small molecule)
Sponsor. Eli Lilly. Mechanism. Oral GLP-1 receptor agonist (small-molecule, non-peptide). Phase. Phase 3. Earliest plausible decision. 2027. What it changes. First true oral GLP-1 with no food-and-water restrictions; closes the access gap for patients who decline injections.
Read the dedicated post on orforglipron.
GLP-1/GIP dual agonists
2. CagriSema (cagrilintide + semaglutide fixed-dose combination)
Sponsor. Novo Nordisk. Mechanism. Fixed-dose combination of an amylin analog (cagrilintide) and a GLP-1 agonist (semaglutide). Phase. Phase 3 (REDEFINE program), readouts already reported. Earliest plausible decision. Within 12 to 18 months — the earliest plausible decision on the watchlist. What it changes. First combination regimen with fat-to-lean composition data that meaningfully differentiates from monotherapy; raises the prescribing ceiling.
Read the dedicated post on cagrilintide-semaglutide composition.
GLP-1/Glucagon dual agonists
3. Survodutide
Sponsor. Boehringer Ingelheim and Zealand Pharma. Mechanism. Dual GLP-1 and glucagon receptor agonist. Phase. Phase 3 (SYNCHRONIZE program) for obesity and MASH. Earliest plausible decision. 2027 to 2028. What it changes. Mechanism stacks GLP-1 appetite reduction with glucagon-driven energy expenditure; alternative to GLP-1/GIP dual agonism.
Read the dedicated post on survodutide.
4. Mazdutide
Sponsor. Innovent Biologics and Eli Lilly. Mechanism. Dual GLP-1 and glucagon receptor agonist. Phase. Phase 3 in the US; approved in China for chronic weight management. Earliest plausible US decision. 2027 to 2028. What it changes. Adds a US-relevant dual GLP-1/glucagon option with substantial Chinese real-world experience by approval time.
Read the dedicated post on mazdutide.
5. Pemvidutide
Sponsor. Altimmune. Mechanism. Dual GLP-1 and glucagon receptor agonist. Phase. Phase 3 in obesity and MASH. Earliest plausible decision. 2027 to 2028. What it changes. MASH-positioned dual agonist with phase 2 histology data; potentially MASH-specific labeling.
Read the dedicated post on pemvidutide.
GLP-1/GIP/Glucagon triple agonists
6. Retatrutide
Sponsor. Eli Lilly. Mechanism. Triple GLP-1, GIP, and glucagon receptor agonist. Phase. Phase 3 (TRIUMPH program). Earliest plausible decision. 2027. What it changes. Highest weight-loss efficacy in the late-stage pipeline (phase 2 mean approximately 24% at 48 weeks at the high dose); raises the ceiling for what is achievable with GLP-1-class therapy.
Read the dedicated post on retatrutide.
Peptide-antibody conjugates
7. MariTide (maridebart cafraglutide)
Sponsor. Amgen. Mechanism. Peptide-antibody conjugate; GLP-1 agonist + GIP antagonist. Phase. Phase 3. Earliest plausible decision. 2027 to 2028. What it changes. First monthly-dosing GLP-1-class compound; meaningfully different administration profile from weekly injectables.
Read the dedicated post on MariTide.
Amylin analogs (non-GLP-1 mechanism)
8. Petrelintide
Sponsor. Zealand Pharma. Mechanism. Long-acting amylin analog (monotherapy). Phase. Phase 3. Earliest plausible decision. 2027 to 2028. What it changes. First mechanistically distinct (non-GLP-1-class) compound to approach approval in modern obesity pharmacology; mechanistic diversity for patients who do not tolerate or respond to GLP-1.
Read the dedicated post on petrelintide.
MASH-focused metabolic peptides
9. Tirzepatide for MASH (label expansion)
Sponsor. Eli Lilly. Mechanism. Approved GLP-1/GIP dual agonist; phase 3 in MASH for label expansion. Phase. Phase 3 in MASH. Earliest plausible decision. 2027. What it changes. Approved compound with new MASH-specific label opens prescribing in liver-focused indications.
10. Semaglutide for MASH (label expansion)
Sponsor. Novo Nordisk. Mechanism. Approved GLP-1 agonist; phase 3 in MASH. Phase. Phase 3. Earliest plausible decision. 2027. What it changes. Existing approved compound with potential MASH-specific labeling; expands clinical positioning.
GHRH and growth-hormone-axis compounds
11. Tesamorelin label expansion / next-generation GHRH analogs
Sponsor. Theratechnologies (tesamorelin) and others in development. Mechanism. GHRH receptor agonism. Phase. Various; tesamorelin is approved with label expansion potentially under study. Earliest plausible decision. Ongoing through 2026-2028. What it changes. Broader GHRH-axis prescribing in adult metabolic and recovery contexts.
Read the dedicated post on sermorelin and the GHRH class.
Body-composition-focused compounds
12. Bimagrumab and the activin/myostatin pathway
Sponsor. Versanis Bio (acquired by Eli Lilly) and pipeline competitors. Mechanism. Activin type II receptor antagonism / myostatin pathway modulation. Phase. Phase 2/3 in body-composition indications, including potentially in combination with GLP-1. Earliest plausible decision. 2027 to 2028. What it changes. First non-GLP-1 mechanism specifically targeting body composition (lean-mass preservation, muscle accretion); potential combination partner with GLP-1 to address fat-to-lean ratio in weight-loss regimens.
How to read this watchlist through 2026 and 2027
The 12 compounds above represent meaningful phase 3 development across mechanism classes. The realistic interpretation:
Most likely to be approved first: CagriSema and orforglipron, with submissions plausible in 2026 and decisions plausible in mid-2027 to early-2028.
Highest-efficacy candidate: Retatrutide. Phase 2 weight-loss data is the highest in the pipeline; phase 3 will determine whether the trial-effect-size translates.
Most differentiated administration profile: MariTide. Monthly dosing.
Most differentiated mechanism: Petrelintide. Non-GLP-1-class.
Most differentiated indication positioning: Pemvidutide. MASH-focused.
Highest commercial uncertainty: The smaller-developer compounds (pemvidutide, petrelintide). Phase 3 success matters; commercialization strategy after approval is variable.
The compounds will not all be approved. Phase 3 has a real failure rate. Some compounds will be delayed by manufacturing or regulatory issues. Some will fail on safety. The watchlist is a list of what is plausible, not a list of what is guaranteed.
What this means for TelePeptide patients in 2026
For patients on currently approved GLP-1-class therapy:
- Continue current treatment. The pipeline does not change current prescribing. None of the 12 compounds are approved.
- Tracking the watchlist is reasonable. When approval occurs, the prescribing options expand. Tracking which compound is at which phase informs the conversation about whether to switch in 2027 or 2028.
- No legitimate prescriber writes investigational compounds in 2026. This is the recurring point. Compounded "retatrutide" or "MariTide" or "mazdutide" sold through any source in 2026 is not the actual compound.
For patients considering starting peptide therapy:
- Approved options are the basis for current prescribing. Semaglutide, tirzepatide, liraglutide for GLP-1; sermorelin and tesamorelin for GHRH. Decisions about future switching to compounds on the watchlist are forward-looking and revisited at approval.
- Mechanism-class diversity is increasing. By 2028, the prescribing landscape will likely include amylin agonism, peptide-antibody conjugates, and triple agonism, in addition to the current GLP-1 and GLP-1/GIP options. Patients who do not tolerate or respond to current options may have new options in the late-2027 window.
TelePeptide's prescribing posture across the watchlist
The same posture applies uniformly to every compound on this list:
- Approval before prescribing. No investigational compound is offered until FDA approval.
- Approved branded products through licensed pharmacy channels. When approval occurs, the supply path is the FDA-approved branded product through licensed pharmacies — not compounded versions claiming to be the same.
- Standard of care. Each approval is incorporated into clinical workflow with appropriate intake updates, prescribing guidelines, and ongoing-monitoring protocols.
This is not a marketing posture. It is the standard-of-care posture for prescribing investigational compounds: not until approval.
Quarterly update cadence
This watchlist is maintained quarterly. The Q3 2026 update (in July) will incorporate any FDA decisions, advisory committee outcomes, phase 3 readouts, or submission events that occur in the interim. Individual compound posts are updated as material events occur within each program.
Subscribe to the TelePeptide blog or follow updates on the public registry for the next watchlist update.
Bottom line
There are at least 12 peptides in late-stage clinical development with realistic FDA decision windows between 2026 and 2028. The list spans GLP-1 mono-agonists, dual agonists across multiple receptor combinations, triple agonists, peptide-antibody conjugates, and non-GLP-1-class amylin analogs. None are approved as of May 2026. The earliest plausible decisions are in mid-2027 to early-2028. Patients tracking the pipeline should base 2026 prescribing on currently approved compounds and revisit at the next quarterly watchlist update.
FAQ
Common questions
How many new peptides are realistically coming to market between 2026 and 2028?
There are at least a dozen late-stage compounds with realistic FDA decision windows between 2026 and 2028. Not all of them will be approved on the expected timelines; some will be delayed, some will fail in phase 3, some will reach approval ahead of expectations. The list of 12 below is the watchlist as of May 2026 — the compounds whose approval would meaningfully change the prescribing landscape.
Why are these all GLP-1-class compounds?
They are not. The list includes GLP-1 mono-agonists, GLP-1/GIP dual agonists, GLP-1/glucagon dual agonists, GLP-1/GIP/glucagon triple agonists, peptide-antibody conjugates with GIP antagonism, and a non-GLP-1-class amylin analog. The metabolic-disease pipeline is dominated by GLP-1-class chemistry but includes meaningful mechanistic diversity.
Can I get any of these 12 peptides today?
No, not legitimately. None of the 12 compounds on this watchlist are FDA-approved in the United States as of May 2026. Sources claiming to provide compounded versions of investigational compounds are misrepresenting what they are selling — compounded retatrutide, compounded MariTide, compounded mazdutide are not the actual investigational drugs.
Which of these 12 is most likely to be approved first?
CagriSema (cagrilintide-semaglutide fixed-dose combination) and orforglipron (oral GLP-1 small molecule) are the closest to approval based on phase 3 readout maturity and submission timing as of May 2026. The mid-2027 to early-2028 window is plausible for both. Approval order depends on submission timing and review duration.
Will compounded versions become available after approval?
Some compounds have compoundable architectures (peptides amenable to 503A and 503B compounding); others do not (peptide-antibody conjugates, biologics-grade molecules). The answer is compound-specific. After approval, FDA-recognized shortage pathways may permit compounding of certain approved peptides, but the rules are specific and vary.
How often is this watchlist updated?
TelePeptide updates the pipeline content quarterly. The Q3 and Q4 2026 updates will incorporate any FDA decisions, advisory committee outcomes, phase 3 readouts, or submission events that occur in the interim. Each individual compound also has a dedicated post that is maintained in parallel.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.